Organisation paid for research Program year 2021 Source: CMS Open Payments

Collaborative Neuroscience Network Incorporated

Neither a doctor nor a teaching hospital

Research payments

$796,428

44 payments

Through program year 2021, Collaborative Neuroscience Network Incorporated is reported as receiving $796,428 in research payments, across 44 payments.

By program year

2 rows
Year Kind Amount Payments
2021 Research $2,009 3
2019 Research $794,419 41

Breakdown

Who paid Research payments · program years 2019–2021
  1. Allergan Inc. $796,428 44 payments
Studies the money was for Research payments · program years 2019–2021
  1. Double-Blind, Placebo Controlled, Single and Multiple-Dose Study of Agn-241751 in Adult Participants With Major Depressive Disorder $599,252 2 payments
  2. Phase Iia US Pop W Sod 3125-201-002 $115,681 18 payments
  3. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $38,277 10 payments
  4. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $21,708 9 payments
  5. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $10,000 1 payment
  6. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $9,500 1 payment
  7. A Double-Blind, Placebo-Controlled Study of Cariprazine As Adjunctive Therapy in Major Depressive Disorder $689 1 payment
  8. A Double-Blind, Placebo-Controlled, Randomized Withdrawal,Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in A Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia $660 1 payment
  9. Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Or Most Recent Episode Is Manic $660 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record